Stockreport

Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI

Spero Therapeutics, Inc.  (SPRO) 
Last spero therapeutics, inc. earnings: 3/16 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: investors.sperotherapeutics.com/overview
PDF FDA meeting supports single pivotal Phase 3 clinical trial of SPR994 in cUTISPR994 IND submitted and ADAPT-PO Phase 3 startup activities underway CAMBRIDGE, Mass., Jan. [Read more]